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Inﬂuenza B virus infections are less common than infections caused by inﬂuenza A virus in critically ill patients, but similar
mortality rates have been observed for both inﬂuenza types. Pneumonia caused by inﬂuenza B virus is uncommon and has been
reported in pediatric patients and previously healthy adults. Critically ill patients with pneumonia caused by inﬂuenza virus may
develop acute respiratory distress syndrome. We describe the clinical course of a critically ill patient with diﬀuse large B-cell
lymphoma nongerminal center B-cell phenotype who developed acute respiratory distress syndrome caused by inﬂuenza B virus
infection. This paper emphasizes the need to suspect inﬂuenza B virus infection in critically ill immunocompromised patients
with progressive deterioration of cardiopulmonary function despite treatment with antibiotics. Early initiation of neuraminidase
inhibitor and the implementation of guidelines for management of severe sepsis and septic shock should be considered.
1.Introduction
Inﬂuenza B virus infections are less common than infections
caused by inﬂuenza A virus in critically ill patients, but
similar mortality rates have been observed for both inﬂuenza
types [1]. The pulmonary complications related with
inﬂuenza include primary viral pneumonia, secondary bac-
terial pneumonia, and pneumonia attributable to unusual
pathogens [2]. Pneumonia caused by inﬂuenza B virus is
uncommon and has been reported in pediatric patients
[3] and previously healthy adults [4]. From 22 May 2011
to 4 June 2011, National Inﬂuenza Centres (NICs) from
65 countries reported as positive for inﬂuenza viruses 483
specimens of which 233 (48.2%) were typed as inﬂuenza
B[ 5]. At the beginning of 2011, inﬂuenza B has taken
over inﬂuenza A H1N1 virus as the most dominant strain
in circulation in some countries like United Kingdom [6].
We describe the clinical course of a critically ill patient
with diﬀuse large B-cell lymphoma nongerminal center B-
cell phenotype who developed acute respiratory distress
syndrome (ARDS) caused by inﬂuenza B virus infection.
2.CaseReport
A 69-year-old woman with a medical history of hypothy-
roidism was treated with levothyroxine. She was diagnosed
with diﬀuse large B-cell lymphoma nongerminal center B-
cell phenotype with nasopharyngeal involvement stage IVE
(international prognostic index >3) on September 22, 2010.
The immunohistochemical study from cervical lymph node
was positive for CD3, CD20, B-cell lymphoma (BCL) 2,
BCL-6, and multiple myeloma oncogene 1; tumor cells were
negativeforCD10.Shewastreatedwith5cyclesofrituximab,
cyclophosphamide,doxorubicin,vincristine,andprednisone
(R-CHOP). In November 2010, the patient received the last
cycle of R-CHOP. Over the last two months, her absolute2 Case Reports in Medicine
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Figure 1: Chest radiographs of a patient with acute respiratory distress syndrome primary caused by inﬂuenza B virus infection. (a) On
admission, no pulmonary inﬁltrates were found. (b) Chest radiograph shows bilateral diﬀuse alveolar opacities. (c) Chest radiograph a day
prior to discharge shows complete resolution of the bilateral diﬀuse alveolar opacities.
lymphocyte count was <1.0 × 109/L. She had not received
inﬂuenza vaccine.
OnDecember28,2010,shewasadmittedtoTheNational
Cancer Institute located in Mexico City. On admission,
she related a history of mild nonproductive cough and
fever (38.8◦C) for 2 days. On admission, no pulmonary
inﬁltrates were found in the patient on chest radiograph
(Figure 1(a)), her leucocytes count was 0.8 × 109/L, and
the SpO2 was 90% at room air. She was treated with
ceftriaxone and clarithromycin. For the next 2 days, the
patient persisted with fever and developed acute respiratory
failure, and due to her critical condition, she was admitted
to Intensive Care Unit (ICU); chest radiograph showed
bilateraldiﬀusealveolaropacitiesconsistentwithpneumonia
(Figure 1(b)), and due to further respiratory deterioration
(PaO2/FIO2 ratio was 91mmHg), the patient was intubated
andinvasivemechanicalventilationwasstarted.Sherequired
8cmH 2O of positive end-expiratory pressure. The acute
physiology and chronic health evaluation (APACHE) II and
sequential organ failure assessment scores on admission to
ICU were 16 and 11 points, respectively.
She was treated for septic shock and primary acute res-
piratory distress syndrome (ARDS). Real-time polymerase
chain reaction (RT-PCR) of nasopharyngeal swab, expecto-
ration, and blood cultures were taken, and the antibiotic
therapy was empirically changed to meropenem every 8
hours for ten days; the clarithromycin was stopped by an
increaseinliverfunctioningtests.Duetoclinicalsuspicionof
inﬂuenza virus and bacterial coinfection, oseltamivir 75mg
every 12 hours was added on day 2 after admission and
continued for 10 days. Expectoration and blood cultures
were negative, but the RT-PCR was positive for inﬂuenza B
virus.Shereceivedtreatmentwithvasoactivedrugsandstress
dose corticosteroids for 5 days. The patient progressively
improved, and she was successfully weaned from mechanical
ventilation after 6 days. The lengths of ICU and hospital
stays were 10 and 17 days, respectively. Chest radiograph a
day prior to discharge showed complete resolution of the
bilateral diﬀuse alveolar opacities (Figure 1(c)). After further
recovery, the patient was discharged home.
3. Discussion
ThispatientwithdiﬀuselargeB-celllymphomanongerminal
center B-cell phenotype presented ARDS primary caused by
inﬂuenza B virus infection and septic shock.
Patients with pneumonia caused by inﬂuenza virus may
develop acute respiratory failure and ARDS. During the
2009 H1N1 inﬂuenza pandemic, inﬂuenza (H1N1) A virus
infection was an important cause of acute lung injury or
ARDS [7].
The pathophysiologic mechanisms for the development
of ARDS are still not fully understood [8]. A mouse model
developed by Smith et al. [9] characterized the pathology
and immunology of inﬂuenza-infected mice with severe
secondary bacterial pneumonia and sepsis. They found ele-
vated levels of both pro- and anti-inﬂammatory molecules.
These elevated levels may induce tissue damage and interfere
with the ability of the host to clear the inciting organisms
[9]. During the acute phase of ARDS, there is an intense
inﬂammatory process in the lung with sequential activation
of cytokines, chemokines, and secretion of proteases, as
well as concomitant collagen synthesis. On the other hand,
the early phase of ARDS is characterized by increased
permeability edema, interpreted as accumulation of protein-
rich edema ﬂuid into the air spaces [10].
Recently, Shieh et al. [11] described pathological studies
on autopsy samples from 100 patients with fatal 2009
H1N1 virus infection that occurred during 2009 in the
United States. The most frequent histopathological ﬁndings
in lung tissues were edema (63%), hyaline membranes
(59%), hemorrhage (58%), and inﬂammation (48%). In
their paper [11], the 74% of case patients did not have
conﬁrmatory test results of bacterial coinfection. The clinical
presentation of the critically ill patients with inﬂuenza
B infection is characterized by acute respiratory failure,Case Reports in Medicine 3
refractory hypoxemia, and bilateral alveolar inﬁltrates on
chest radiograph [3, 4]. Approximately 70% of critically ill
patients with inﬂuenza (H1N1) A virus infection required
mechanical ventilation [2], and they had high mortality rate
[12–14]. Inﬂuenza B virus has been identiﬁed (14%) in
critically ill patients admitted to ICU [1, 15]. Furthermore,
high prevalence of ARDS (23%) and mortality rate greater
than 50% [1] in patients with inﬂuenza have been described.
The patients who are immunocompromised may have
severe inﬂuenza infection. In a retrospective study [16] that
included 100 immunocompromised patients with inﬂuenza,
only 20% had inﬂuenza B virus infection. In this study [16],
60.4% of patients with pneumonia were admitted to ICU,
of these patients, 34.3% required mechanical ventilation and
45.4% died.
In clinical practice, the mechanical ventilation strategies
for patients with ARDS caused by inﬂuenza virus infection
should be similar to those used in patients with ARDS due
to other causes. The current evidence suggests that lung
protective ventilation should be implemented in ventilator
management of patients with ARDS because this strategy
has demonstrated a signiﬁcant mortality beneﬁt [17]. Our
patient received ventilatory management with this strategy
which includes a target tidal volume of 6mL/kg (predicted
body weight) and the initial upper limit goal for plateau
pressures ≤30cmH2O.
In this paper, the patient showed clinical deterioration
despite treatment with antibiotics and oseltamivir was
started. The ARDS and fever could have been caused by
otherinfectionsthatwerenotdetected,sincemostlaboratory
tests were carried out after antibiotic treatment was initiated.
The oral neuraminidase inhibitor oseltamivir has been
studied at doses of 75mg or 150mg twice daily for ﬁve
days in immunocompetent subjects with seasonal inﬂuenza
[18]. Both dose levels of oseltamivir resulted in statistically
signiﬁcant reductions in the duration and severity of illness
among those infected with inﬂuenza virus [18]. Prolonged
inﬂuenzavirusrespiratorytractinfection(AH3N2,AH1N1,
and B) has been observed in immunocompromised patients
with lymphopenia and is associated with development of
inﬂuenza lower respiratory tract infection [19, 20]. The
recommended dose is 75mg twice daily for ﬁve days;
however, longer duration and double dose of oseltamivir
could be considered in immunosuppressed patients [21, 22].
Recent data published by Ariano et al. [23] suggest that a
higher dose of oseltamivir is unlikely to be necessary in such
cases. Oseltamivir was well absorbed enterically in critically
ill patients with suspected or conﬁrmed pandemic (H1N1)
inﬂuenza who required admission to the ICU. The dosage of
oseltamivir75mgtwicedailyachievedtroughconcentrations
for the carboxylate metabolite that are well above any phar-
macodynamicprobabilitythresholdformaximuminhibition
of virus [23]. Early initiation (within 48 to 96 hours from
onset) of oseltamivir for patients with inﬂuenza infection
requiring hospitalization has been associated with shorter
length of hospital stay [24] and improved survival [25].
Schnell et al. [16] recently reported that in immuno-
compromised patients with inﬂuenza, hematological malig-
nancies, and inﬂuenza A infection independently predicted
pneumonia. Furthermore, the development of ARDS and
the history of immunosuppression have been described as
independent risk factors for hospital mortality in critically
ill patients with conﬁrmed inﬂuenza virus infection [1].
Critically ill patients with complicated inﬂuenza pneumonia
with an APACHE II score >20 and a PaO2/FiO2 ratio <150
have increased risk of death [26].
Our ICU routinely implements the guidelines for man-
agement of severe sepsis and septic shock [27, 28], because
they have been associated with a signiﬁcant reduction in
hospital mortality in patients with severe sepsis and septic
shock from 37% to 30.8% (P = 0.001) [29].
4. Conclusion
This paper emphasizes the need to suspect inﬂuenza B
virus infection in critically ill immunocompromised patients
with progressive deterioration of cardiopulmonary function
despite treatment with antibiotics. Early initiation of neu-
raminidase inhibitor and the implementation of guidelines
for management of severe sepsis and septic shock should be
considered.
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